[144] Jade Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 Notice of Proposed Sale filed by Jade Biosciences indicates a planned sale of 28,977 shares with an aggregate market value of $303,678.96 through Merrill Lynch on the Nasdaq exchange, scheduled for June 25, 2025.

The securities were originally acquired through a Private Placement from the issuer on June 4, 2021, purchased with cash. The total outstanding shares are 28,985,019.

Recent Trading Activity:

• Atlas Ventures Fund XII LP and Atlas Ventures Associates XII LP have conducted multiple sales in the past 3 months
• Most recent transactions occurred June 24-25, 2025, with Atlas Ventures Fund XII LP selling 16,132 shares ($167,776.03)
• Total combined recent sales by Atlas entities amount to approximately 22,429 shares

Positive

• None.

Negative

• Venture capital firm Atlas Ventures has sold approximately 22,429 shares worth $236,100 over the past two months, indicating continued institutional selling pressure

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Jade Biosciences, Inc.	Merrill Lynch One Bryant Park New York NY 10036	28977	303678.96	28985019	06/25/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2021	Private Placement	Issuer			28977	06/04/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Ventures Associates XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	48	498.84
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	5883	64061.73
Atlas Ventures Associates XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	131	1300.54
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	16132	167776.03
Atlas Ventures Associates XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/25/2025	235	2462.80

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of JBIO stock are being proposed for sale according to the Form 144 filing from June 28, 2025?

According to the Form 144 filing, 28,977 shares of Jade Biosciences, Inc. (JBIO) are proposed to be sold through Merrill Lynch, with an aggregate market value of $303,678.96.

When did the JBIO insider originally acquire the shares being sold?

The shares were originally acquired on June 4, 2021 through a Private Placement from the issuer, with payment made in cash on the same date.

What is JBIO's total shares outstanding as reported in the Form 144?

According to the Form 144 filing, Jade Biosciences, Inc. (JBIO) has 28,985,019 shares outstanding.

What recent insider sales of JBIO stock were reported in the three months prior to this Form 144?

In the three months prior, there were several sales by Atlas Ventures entities: Atlas Ventures Fund XII LP sold 5,883 shares on May 6, 2025 ($64,061.73) and 16,132 shares on June 24, 2025 ($167,776.03). Atlas Ventures Associates XII LP made smaller sales: 48 shares on May 6, 131 shares on June 24, and 235 shares on June 25, 2025.

What is the planned sale date for the JBIO shares according to the Form 144?

The Form 144 indicates an approximate date of sale of June 25, 2025, to be executed on the Nasdaq exchange through Merrill Lynch.